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IMPORTANCE Atypical parkinsonian syndromes (APS), including progressive supranuclear
palsy (PSP), corticobasal syndrome (CBS), andmultiple system atrophy (MSA), may be
difficult to distinguish in early stages and are oftenmisdiagnosed as Parkinson disease (PD).
The diagnostic criteria for PSP have been updated to encompass a range of clinical subtypes
but have not been prospectively studied.
OBJECTIVE To define the distinguishing features of PSP and CBS subtypes and to assess their
usefulness in facilitating early diagnosis and separation from PD.
DESIGN, SETTING, PARTICIPANTS This cohort study recruited patients with APS and PD from
movement disorder clinics across the United Kingdom from September 1, 2015, through
December 1, 2018. Patients with APS were stratified into the following groups: those with
Richardson syndrome (PSP-RS), PSP-subcortical (including PSP-parkinsonism and
progressive gait freezing subtypes), PSP-cortical (including PSP-frontal and PSP-CBS overlap
subtypes), MSA-parkinsonism, MSA-cerebellar, CBS–Alzheimer disease (CBS-AD), and
CBS–non-AD. Data were analyzed from February 1, throughMay 1, 2019.
MAIN OUTCOMES ANDMEASURES Baseline group comparisons used (1) clinical trajectory;
(2) cognitive screening scales; (3) serum neurofilament light chain (NF-L) levels; (4) TRIM11,
ApoE, andMAPT genotypes; and (5) volumetric magnetic resonance imagingmeasures.
RESULTS A total of 222 patients with APS (101 with PSP, 55 with MSA, 40with CBS, and 26
indeterminate) were recruited (129 [58.1%]male; mean [SD] age at recruitment, 68.3 [8.7]
years). Age-matched control participants (n = 76) and patients with PD (n = 1967) were
included for comparison. Concordance between the antemortem clinical and pathologic
diagnoses was achieved in 12 of 13 patients with PSP and CBS (92.3%) undergoing
postmortem evaluation. Applying theMovement Disorder Society PSP diagnostic criteria
almost doubled the number of patients diagnosed with PSP from 58 to 101. Forty-nine of 101
patients with reclassified PSP (48.5%) did not have the classic PSP-RS subtype. Patients in
the PSP-subcortical group had a longer diagnostic latency and amore benign clinical
trajectory than those in PSP-RS and PSP-cortical groups. The PSP-subcortical group was
distinguished from PSP-cortical and PSP-RS groups by cortical volumetric magnetic
resonance imagingmeasures (area under the curve [AUC], 0.84-0.89), cognitive profile
(AUC, 0.80-0.83), serumNF-L level (AUC, 0.75-0.83), and TRIM11 rs564309 genotype.
Midbrain atrophy was a common feature of all PSP groups. Eight of 17 patients with CBS
(47.1%) undergoing cerebrospinal fluid analysis were identified as having the CBS-AD
subtype. Patients in the CBS-AD group had a longer diagnostic latency, relatively benign
clinical trajectory, greater cognitive impairment, and higher APOE-ε4 allele frequency than
those in the CBS–non-AD group (AUC, 0.80-0.87; P < .05). SerumNF-L levels distinguished
PD from all PSP and CBS cases combined (AUC, 0.80; P < .05).
CONCLUSIONS AND RELEVANCE These findings suggest that studies focusing on the PSP-RS
subtype are likely to miss a large number of patients with underlying PSP tau pathology.
Analysis of cerebrospinal fluid defined a distinct CBS-AD subtype. The PSP and CBS subtypes
have distinct characteristics that may enhance their early diagnosis.
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A typical parkinsonian syndromes (APS) consist of aheterogeneous group of neurodegenerative disordersthat include progressive supranuclear palsy (PSP),
corticobasal syndrome (CBS), and multiple system atrophy
(MSA).Atypical parkinsonian syndromes are characterizedby
amore rapiddeteriorationandpoorer levodopa response than
is usually seen inParkinsondisease (PD).1 In addition,APS are
rarer than PD, with an estimated combined prevalence of 10
to 18 per 100000 population.2-4 Within APS, there is a high
degree of clinical overlap, particularly in early disease, lead-
ing to greater misdiagnosis than occurs in PD.5 The lack of
proven disease-specific diagnostic markers means that post-
mortemneuropathologic analysis is the criterion standard for
confirming the clinical diagnosis.
Therecent therapeutic trialsofdavunetide6andtideglusib7
in PSP–Richardson syndrome (PSP-RS) did not result in im-
proved outcomes. The power of clinical trials is limited by in-
dividual variability in disease progression and misclassifica-
tion. Moreover, trials that focus on classic presentations may
not be applicable to the full disease spectrum. Accurate diag-
nosis andprognosis basedon clinical andbiomarker datamay
increase statistical power and reduce the required sample size
for trials.8 The new era of potential disease-modifying thera-
pies for APS has made the need for early and accurate bio-
marker-supported clinical diagnosis even greater.
The pathologic features of PSP are characterized by
4-repeat tau (4RT) neuronal and glial lesions predominantly
in the basal ganglia, brainstem, and cerebellar structures. The
classic clinical phenotype of PSP, PSP-RS,9wasdetailed in the
National Institute of Neurological Disorders/Society for PSP
(NINDS-SPSP) operational diagnostic criteria of 1996.10 Re-
cently, PSP-RS and other non-RS clinical subtypes with un-
derlying PSP pathologic features, such as PSP-parkinsonism
andprogressive gait freezing (PSP-PGF),11 have been incorpo-
rated in theMovementDisorder Society (MDS) PSP clinical di-
agnostic criteria12 with independent neuropathologic valida-
tion studies showing improved sensitivity comparedwith the
NINDS-SPSP criteria.13 These new criteria also recognize the
commoncognitive presentations of PSP, including changes in
behavior and speech and language.
Corticobasal syndrome is a clinical syndrome character-
ized by progressive asymmetrical limb apraxia, parkinson-
ism,dystonia, andparticular cognitive impairments.14Theun-
derlying neuropathologic features of CBS are heterogeneous,
with corticobasal degeneration (CBD), PSP, Alzheimer dis-
ease (AD), andTARDNA-bindingprotein43pathologic changes
seen at postmortem, even when using the clinical consensus
criteria.15,16 Multiple system atrophy is an α-synuclein–
linked oligodendrogliopathy manifesting with variable com-
binationsofprogressiveautonomic failure, parkinsonismwith
poor levodopa response, and cerebellar ataxia.17
Herein, we describe the UK-wide Progressive Supra-
nuclear Palsy–Corticobasal Syndrome–Multiple System Atro-
phy(PROSPECT)studyandcompareourbaselinedatawith that
of patientswithPD in theUK-wideTrackingParkinson’s study
to provide a comprehensive prospective picture of the diag-
nosis and clinical features of PSP and CBS. A strength of the
PROSPECTstudywas thebreadthofclinical subtypes thatwere
studiedsystematicallywithmultiple candidatebiomarkers, in-
cluding indeterminate cases that lay outside of diagnostic cri-
teriawhen thestudywas startedbut cameto liewithin thecur-
rent classifications of APS after publication of the MDS PSP
critieria.12Weexamined clinical, cognitive, fluid, genetic, and
imaging biomarkers and performed group comparisons, in-
cluding receiver operating characteristic curves for patient
classification.
Methods
Study Design
The PROSPECT study natural history cohort consists of 7 UK
study sites (University College London [UCL], Oxford, Cam-
bridge, Newcastle, Brighton, Newport, and Manchester). We
obtained study-wide ethical approval from the UCL Queen
Square Institute of Neurology research ethics committee, re-
cruited participants, and obtained written informed consent
from September 1, 2015, through December 1, 2018. We in-
vited all participants to register for postmortem brain dona-
tion at 1 of 4 UK brain banks (Queen Square [London], Cam-
bridge, Oxford, and Manchester). Tracking Parkinson’s is a
UK-wide longitudinal study of PD. Participants with a base-
line clinical diagnosis of PD at 72 sites in theUnitedKingdom,
withmulticenter ethics committee and local research andde-
velopment department approvals, were recruited and pro-
videdwritten informedconsent fromJanuary 1, 2012, through
December 31, 2014.18 Postmortemdata frompatientswith PD
in theTrackingParkinson’s studywerenot available for analy-
sis.This study followed theStrengthening theReportingofOb-
servational Studies in Epidemiology (STROBE) reporting
guideline.
Participants
Wedefined patients entering the study as having PSP, follow-
ing the NINDS-SPSP criteria10; CBS, following the Armstrong
criteria14; orMSA, following the revised Gilman criteria.17We
Key Points
Questions What are the distinguishing features of progressive
supranuclear palsy and corticobasal syndrome subtypes and how
can they be distinguished from Parkinson disease?
Findings In this cohort study of 222 patients with atypical
parkinsonian syndromes, recently defined progressive
supranuclear palsy subtypes are almost as common as classic
Richardson syndrome and share midbrain atrophy as a common
hallmark. Distinct patterns of clinical trajectory, cognitive profile,
serum neurofilament light chain level, genetic, and volumetric
magnetic resonance imagingmeasures helped to distinguish the
clinical subtypes of progressive supranuclear palsy and
corticobasal syndrome; clinical trajectory and serum
neurofilament light chain levels distinguished Parkinson disease
from progressive supranuclear palsy and corticobasal syndrome.
Meaning This study suggests that subtypes of progressive
supranuclear palsy and corticobasal syndrome have distinct
characteristics that may enhance their early diagnosis.
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also included patients with progressive movement or cogni-
tive disorders, thought likely to have APS (based on having
atypical clinical features for PD) but not meeting any of the
above diagnostic criteria, as indeterminate (IDT) cases. Re-
cruited control participants included a spouse or a friend of
the case or came through the Join Dementia Research volun-
teer registry.CaseswithPDfromtheTrackingParkinson’s study
werediagnosedusing theQueenSquareBrainBankclinical di-
agnostic criteria.19
Phenotyping
WereclassifiedPROSPECTstudycaseswith adiagnosis of PSP,
CBS, or IDT according to currentMDS PSP criteria12 at the end
of baseline recruitment.20 All reclassified PSP cases fulfilled
at least “possible” diagnostic criteria. We stratified PSP cases
intoPSP-RS,PSP-subcortical, andPSP-corticalgroups.ThePSP-
subcortical group includes caseswithPSP-parkinsonism,PSP-
PGF, and PSP-oculomotor; the PSP-cortical group includes
cases with PSP-CBS overlap and PSP-frontal.
Baseline CBS cases with cerebrospinal fluid (CSF) evi-
dence of underlying AD pathologic features (described in the
Fluid Biomarkers subsection below)were defined as CBS-AD,
and those with normal CSF analysis were defined as CBD-
4RT because they are likely to have underlying CBD or PSP
pathologic features. Cases of CBS without CSF or postmor-
tem examination were defined as CBS-unknown. Baseline
MSA cases were divided into MSA-parkinsonism and MSA-
cerebellar groups according to the revised Gilman criteria.17
CaseswithPDwhohavehadachange inclinicaldiagnosis since
their baseline Tracking Parkinson’s clinical assessment were
excluded from this study.
Clinical Assessments
We completed core and optional study assessments at
baseline. These assessments will be repeated after 6, 12, 24,
and 36 months of follow-up, with brief assessments at the
48- and 60-month study visits (eTables 1 and 2 in the
Supplement). At each study visit, a neurological history was
obtained, and an examination was performed. The PSP Rat-
ing Scale21 (scores range from 0-100, with higher scores indi-
cating greater impairment) for PSP, CBS, and IDT cases or the
Unified Multiple System Atrophy Rating Scale (scores range
from 0-104, with higher scores indicating greater
impairment)22 for MSA cases was administered by a physi-
cian. In addition, all cases were assessed using the MDS Uni-
fied Parkinson’s Disease Rating Scale parts II (scores range
from 0-52, with higher scores indicating greater impairment)
and III (scores range from 0-132, with higher scores indicat-
ing greater impairment)23 and the Schwab and England
Activities of Daily Living Scale (SEADL; scores range from
0-100, with lower scores indicating greater impairment).24
Cases and controls were screened for cognitive dysfunction
using the Montreal Cognitive Assessment (MoCA; scores
range from 0-30, with higher scores indicating greater
impairment).25 Addenbrooke’s Cognitive Examination 3
(ACE-III)26 and Edinburgh Cognitive and Behavioural ALS
(Amyotrophic Lateral Sclerosis) Screen27 were administered
as additional, optional cognitive screening assessments.
Cases with PD from the Tracking Parkinson’s study under-
went baseline testing with the MDS Unified Parkinson’s Dis-
ease Rating Scale parts II and III, SEADL, and MoCA.
Fluid Biomarkers
We measured serum neurofilament light chain (NF-L) levels
in a subset of PROSPECT and Tracking Parkinson’s cases, and
PROSPECT controls. The CSF total tau (T-tau) and β-amyloid
1-42 (Aβ1-42) levels were measured in a subset of PROSPECT
cases at the UKDementia Research Institute Fluid Biomarker
Laboratory at UCL (eMethods in the Supplement). Caseswith
CBS were stratified into groups with likely underlying AD
pathologic features (CBS-AD),definedascaseswithaCSFT-tau:
Aβ1-42 ratio of greater than 128; likely 4RT pathologic
features (CBS-4RT), defined as caseswith a CSF T-tau:Aβ1-42
ratio of less than 1; and unknown pathologic features
(CBS-unknown), defined as cases with no CSF analysis.
Genetics
Asubset of PROSPECTandTrackingParkinson caseshadDNA
extracted frombloodsamples.DNAwassubsequentlyused for
genotyping and single-nucleotide polymorphism imputation
(eMethods in theSupplement) toobtainMAPT (OMIM157140)
H1/H1, APOE (OMIM 107741) ε4 allele, and TRIM11 (OMIM
607868) rs564309minor allele group frequencies.
Neuroimaging
A subset of PROSPECT participants attended 3 scanning cen-
ters (UCL, Cambridge, and Oxford) and underwent baseline
volumetricT1-weightedmagnetic resonance imaging (MRI) on
3T scanners (Siemens, Prisma, or TRIO) (eMethods in the
Supplement). We combined the basal ganglia (caudate, puta-
men,andpallidum),accumbens,andthalamusascentral struc-
tures for summarizinggroupwise subcortical atrophy. Imaging
data fromTrackingParkinson’sparticipantswerenotavailable.
MSAGroup Data
We have included cases with MSA in the description of our
PROSPECT study cohort and baseline clinical features. How-
ever, the statistical analyses described below and compari-
sons with PD data have been restricted to PSP, CBS, and IDT
casesbecause these caseswere reclassifiedunder theMDSPSP
diagnostic criteria. The analysis of associatedMSAgroupdata
will be published separately.
Statistical Analysis
Datawereanalyzed fromFebruary 1 throughMay1,2019,using
Plink, version 1.9 (Harvard University), GraphPad, version 8
(Prism), andStata, version 15 (StataCorpLLC).Formissingdata
in clinical scales, an adjusted mean score was used if at least
80% of the assessment was complete.
Group comparisons of clinical, cognitive, and biomarker
measures were made using logistic regression analyses with
sex, age at symptom onset, and disease duration at testing as
covariates.We calculated the clinical disease trajectory by di-
viding PSP Rating Scale andMDSUnified Parkinson’s Disease
Rating Scale parts II and III scores at baseline by the number
ofyears since reportedmotorsymptomonset, assumingascore
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology Published online December 20, 2019 E3
Downloaded From: https://jamanetwork.com/ by a Cardiff University User  on 01/15/2020
of 0 immediately before symptom onset. For the SEADL, the
clinical disease trajectory was calculated as (100 − baseline
score) divided by the number of years since reported motor
symptom onset, assuming a score of 100 immediately before
symptom onset. Statistical significance for the clinical, cog-
nitive, andbiomarker groupcomparisonsdescribedabovewas
defined as a false discovery rate–corrected, 2-sided P < .05.
Groupcomparisonsof geneticdataweremadeusingFisher ex-
act tests, and statistical significance was defined as a Bonfer-
roni-corrected2-sidedP < .05.Weperformedananalysisof co-
variance on imaging volumetric measures from each brain
region, with diagnosis and sex as factors and age at scan and
total intracranialvolumeascovariates.Regionalmarginalmean
valueswere comparedposthocusingunpaired t tests. The sig-
nificanceofmeandifferenceswas adjustedusing falsediscov-
ery rate correction with 2-sided P < .05 considered signifi-
cant. In addition, receiver operating characteristic curve
analyseswereperformedoncognitive scale, serumNF-L level,
and regional imagingvolumetric values fromgrouppairswith
the area under the curve (AUC) used as a measure of separa-
tion between the groups.
Results
Recruitment and Phenotyping
We analyzed 222 cases with APS (93 female [41.9%] and
129 male [58.1%]; mean [SD] age at recruitment, 68.3 [8.7]
years), 76 controls, and 1967 cases with PD. At study entry,
application of clinical diagnostic criteria, including the
NINDS-SPSPPSPcriteria, identified58caseswithPSP, 55 cases
withMSA, 55 cases with CBS, and 54 IDT cases (Figure 1). Re-
classification of PROSPECT PSP, CBS, and IDT cases was pos-
sible after thepublicationof the 2017MDSPSP criteria, result-
ing in 101caseswithPSP,55caseswithMSA,40caseswithCBS,
and 26 IDT cases (Figure 1). Of note, 15 cases with CBS were
reclassified as PSP-CBS overlap under the MDS PSP diagnos-
tic criteria because they had the presence of slowed vertical
saccades and/or a vertical supranuclear gaze palsy, both of
whichareassociatedwithunderlyingPSPpathologic findings.1
In total, 17 of 40 reclassified CBS cases (42.5%) had CSF
collection, of whom 8 (47.1%) had an AD-like CSF profile.
The following disease groups were defined (Figure 1): PSP-
RS, PSP-subcortical (consisting of PSP-parkinsonism,
PSP-PGF, and PSP–oculomotor predominant subtypes),
PSP-cortical (consisting of PSP-CBS overlap and PSP-frontal
subtypes), MSA-parkinsonism, MSA-cerebellar, CBS-
unknown, CBS-4RT, CBS-AD, and IDT.
Pathologic Confirmation of Diagnosis
Forty-four of 222 cases in the PROSPECT cohort (19.8%) had
died at the point of censoring, with amean (SD) disease dura-
tionof5.9 (2.3)years. Seventeenof44cases (38.6%)hadpatho-
logic confirmation of diagnosis at the Queen Square, Cam-
bridge,Oxford, andManchester brainbankswith concordance
between antemortem clinical and pathologic diagnoses
Figure 1. Recruitment of Patients to the Progressive Supranuclear Palsy–Corticobasal
Syndrome–Multiple SystemAtrophy (PROSPECT) Study
101 With PSP
(MDS PSP criteria)
58 With PSP
(NINDS-SPSP criteria)
19 With PSP-CBS overlap
6 With PSP-frontal
13 With PSP-parkinsonism
1 With PSP-OM
10 With PSP-PGF24 With PSP-subcortical
25 PSP-cortical
52 With PSP-RS
Original diagnostic criteria
Revised diagnostic criteria
23 With MSA-cerebellar
32 With MSA-parkinsonism
40 With CBS
(Armstrong criteria)
55 With MSA
(Gilman criteria)
76 Controls76 Controls
26 IDT54 IDT
23 With CBS-unknown
8 With CBS-AD
9 With CBS-4RT55 With CBS(Armstrong criteria)
55 With MSA
(Gilman criteria)
AD indicates Alzheimer disease;
CBS, corticobasal syndrome;
4RT, 4-repeat tau;
IDT, indeterminate; MDS, Movement
Disorder Society; MSA, multiple
system atrophy;
NINDS-SPSP, National Institute of
Neurological Disorders/Society for
PSP (Progressive Supranuclear Palsy);
OM, oculomotor; PGF, progressive
gait freezing; and RS, Richardson
syndrome.
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achieved in 12of 13 caseswithPSPandCBS (92.3%)
(Table 1).Ofnote, theclinicallydiagnosedcasewith
PSP-RS who had CBD pathologic findings at post-
mortemhad typical featuresof PSP-RSwithnoevi-
denceofapraxia throughout thediseasecourseand
was therefore classified as a case of PSP-RS under
the NINDS-SPSP and MDS diagnostic criteria.
Clinical Features
All PROSPECT cases underwent baseline clinical
testing, whereas baseline clinical data were ob-
tained from1763of 1967 recruitedpatientswithPD
(89.6%) in the Tracking Parkinson’s study. Thirty-
two of 204 patients with PD (15.7%) were ex-
cluded from this analysis owing tomissing data or
a change in diagnosis at the point of data analysis.
The baseline clinical features of reclassified
cases and controls are summarized in Table 1.
There was a long diagnostic delay for CBS-AD
(mean [SD], 4.6 [3.2] years) and PSP-subcortical
(mean [SD], 4.2 [3.2] years) groups compared
with the CBS-4RT (mean [SD], 3.1 [4.7] years) and
PSP-RS (mean [SD], 2.3 [1.8] years) groups. There
was also variation in the burden of disease at
study enrollment as measured by the baseline
PSP Rating Scale and SEADL scores, with the
highest degree of impairment seen in the PSP-RS
(mean [SD] scores, 35.7 [15.1] and 53.3 [18.1],
respectively), PSP-cortical (mean [SD] scores, 39.1
[13.5] and 48.8 [15.0], respectively), and CBS-4RT
(mean [SD] scores, 41.3 [15.6] and 50.1 [19.8],
respectively) groups (Table 1). Clinical trajectory
analyses (Figure 2), in particular the SEADL,
showed that the PSP-subcortical (mean [SD]
decline in score, −8.5 [8.6] points per year),
CBS-AD (mean [SD] decline in score, −12.0 [7.0]
points per year), and PD (mean [SD] decline in
score, −3.9 [5.1] points per year) groups had more
benign disease trajectories than all other groups.
Cognitive Profiles
We evaluated cognitive function using the MoCA,
EdinburghCognitive andBehavioural ALS Screen,
andACE-III. Among the PROSPECT cases and con-
trols, the MoCA was completed in 235 of 243 par-
ticipants (96.7%); theEdinburghCognitive andBe-
haviouralALSscreen, in211of 243 (86.8%); and the
ACE-III, in 223 of 243 (91.8%) (eTable 3 in the
Supplement).The3assessmentswere strongly cor-
related (all comparisons, r > 0.80).Among the 1967
patientswithPD in theTrackingParkinson’s study,
1833 (93.2%) had baseline MoCA testing (eTable 3
in theSupplement).With regard to total scores, the
PD group had better cognition (mean [SD] score,
24.9 [3.6]) compared with the PSP-all (mean [SD]
score, 21.9 [4.7]) and CBS-all (20.4 [7.4]) groups.
The PSP-cortical group was more impaired across
all 3 scales compared with the PSP-RS andTa
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PSP-subcortical groups (falsediscovery ratecorrected,P < .05).
The CBS-AD group had worse cognition in all scales com-
paredwithCBS-4RT,but thestatistical comparisonswere likely
limited by small group sizes, with significance reached only
in MoCA total score (mean [SD] score, 22.9 [5.3] for CBS-4RT
and 12.4 [9.0] forCBS-AD) andACE-III attention,memory, and
language subscale measures (eTable 3 in the Supplement).
Fluid Biomarkers
Testingof serumsamples forNF-L levelswasperformed in 186
of 243 PROSPECT cases and controls (76.5%) and 140 of 1967
PD cases (7.1%) in the Tracking Parkinson’s study. Forty-four
of 167 cases (26.3%) in the PROSPECT study had CSF testing
for T-tau and Aβ1-42 levels.
At the group level, serum NF-L levels in patients with PD
(26.5 pg/L) were significantly higher than in controls (16.4
pg/L) and the PSP-all (47.4 pg/L) and CBS-all (53.1 pg/L)
groups. Serum NF-L levels did not distinguish between the
PSP-all and CBS-all groups (Figure 3). With respect to disease
subgroups, there was a trend toward higher mean serum
NF-L levels in PSP-cortical (58.6 pg/L) vs PSP-RS (45.3 pg/L)
and PSP-subcortical (41.6 pg/L) and in CBS-4RT (52.4 pg/L)
vs CBS-AD (36.5 pg/L) (Figure 3).
Genetics
Genotypedatawereobtained from134of 167PROSPECTcases
(80.2%) and 1566 of 1967 PD cases (79.6%) in the Tracking
Parkinson’s study (eTable 4 in the Supplement). In the analy-
sis of white cases only, we found significantly higher MAPT
H1/H1 frequencies in the PSP-all (88.9%) and CBS-all (78.8%)
groupscomparedwith thePDgroup(67.2%)andreferencecon-
trols (67.1%) (Bonferroni-corrected P < .05). At the subgroup
level, we found significantly higher APOE-ε4 allele frequen-
cies in CBS-AD (35.7%) compared with CBS-4RT (Bonferroni-
corrected P < .05). Although analyses were underpowered to
reach significance, as reported previously,29we found higher
TRIM11 rs564309minor allele frequencies in PSP-subcortical
(15.0%) compared with PSP-RS (7.1%).
Magnetic Resonance Imaging
Volumetric measures from T1-weighted MRI scans were
derived for 108 of 243 PROSPECT cases and controls
Figure 2. Clinical Disease Trajectory Profiles
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Data are expressed as mean (SD [error bars]). Group comparisons are adjusted
for sex and age at symptom onset. AD indicates Alzheimer disease;
CBS, corticobasal syndrome; 4RT, 4-repeat tau; IDT, indeterminate;
MDS UPDRS-II, Movement Disorder Society Unified Parkinson’s Disease Rating
Scale part II; MDS UPDRS-III, MDS UPDRS part III; PD, Parkinson disease;
PSPRS, PSP (Progressive Supranuclear Palsy) Rating Scale; RS, Richardson
syndrome; and SEADL, Schwab and England Activities of Daily Living Scale.
a False discovery rate (FDR)–adjusted P < .05, PSP-subcortical vs PSP-RS and
PSP-cortical.
b FDR-adjusted P < .01, PD vs PSP-all and CBS-all.
c FDR-adjusted P < .05, PD vs PSP-all and CBS-all.
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(44.4%). eTable 5 in the Supplement outlines the differences
in cortical and subcortical volumetric measures across all
groups, with post hoc pairwise group comparisons of each
patient group vs controls and selected comparisons between
patient groups (Table 2). Midbrain atrophy was a consistent
neuroimaging feature in all PSP groups (marginal mean
[SD] volume: 5.99 [0.53] mL in controls; 5.01 [0.54] mL in
PSP-RS; 5.23 [0.54] mL in PSP-subcortical; and 5.16 [0.55]
mL in PSP-cortical). However, there was a dissociation
between subcortical and cortical variants of PSP: the PSP-
subcortical group showed less atrophy in the midbrain,
medulla, and central structures, with relatively preserved
cortical volumes; the PSP-cortical group showed additional
severe frontotemporal atrophy. Corticobasal syndromes
were associated with relative preservation of the pons and
midbrain (marginal mean [SD] volume: 14.72 [1.70] mL and
5.99 [0.53] mL, respectively, in controls; 13.67 [1.68] mL
and 5.54 [0.52] mL, respectively, in CBS-all) but severe atro-
phy of the central structures and cerebral cortex. Atrophy
varied according to whether the CSF AD biomarkers were
positive or not, with especially prominent ventriculomegaly
in cases with CBS-AD (marginal mean [SD] volume: 35.80
[19.25] mL in controls; 60.81 [18.83] mL in CBS-4RT; 75.75
[18.81] mL in CBS-AD). The IDT cases were notable for their
preserved posterior fossa structures, with atrophy of central
structures and cerebral cortex.
Receiver Operating Characteristic Curve Analyses
Receiver operating characteristic curve analyses showed that
PD was distinguished from an APS group, which consisted of
all PSP and CBS cases, using serum NF-L levels (AUC, 0.80)
(eFigure in the Supplement) and the MoCA score (AUC,
0.78). In addition, we highlight measures that had high diag-
nostic accuracy (defined by an AUC ≥ 0.80) in differentiating
between subgroups (Table 2). All cognitive measures (MoCA,
Edinburgh Cognitive and Behavioural ALS Screen, and
ACE-III) differentiated CBS-AD from CBS-4RT (AUC, 0.80-
0.87) and PSP-subcortical from PSP-RS and PSP-cortical
(AUC, 0.80-0.83). In addition, PSP-subcortical was distin-
guished from PSP-RS using serum NF-L levels (AUC, 0.83)
and from PSP-cortical using cortical volumetric MRI mea-
sures (AUC, 0.80-0.89).
Figure 3. Fluid Biomarker Profiles
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Data are expressed as mean (SD [error bars]). Group comparisons are adjusted
for sex, age at symptom onset, and disease duration at testing. Aβ1-42 indicates
β-amyloid 1-42; AD, Alzheimer disease; CBS, corticobasal syndrome;
CSF, cerebrospinal fluid; 4RT, 4-repeat tau; IDT, indeterminate;
NF-L, neurofilament light chain; PD, Parkinson disease; PSP, progressive
supranuclear palsy; RS, Richardson syndrome; and T-tau, total tau.
a False discovery rate (FDR)–adjusted P < .01, controls vs all disease groups.
b FDR-adjusted P < .05, PD vs PSP-all.
c FDR-adjusted P < .05, PD vs CBS-all.
d FDR-adjusted P < .01, CBS-AD vs all other disease groups.
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Discussion
In this cohort study, we assessed a large number of patients
with PSP and CBS recruited to the natural history arm of the
PROSPECTstudy.Although this isnot a community-basedepi-
demiologic study, we recruited patients with APS across the
United Kingdom. We characterized the different clinical
presentations of PSP using the newMDS PSP diagnostic crite-
ria. We identified disease- and subtype-specific markers that
are likely to improve the early and accurate differentiation of
PD fromPSPandCBSand increase thepower of future clinical
trialswithmorehomogeneousdiseasegroups.Webelievethese
findings should have a direct effect on the newera of anti-tau
clinical trials that aimto recruitpatientswithearly-stagePSP.30
Our PSP-RS group data are consistent with data from pa-
tientswithPSP-RS inthedavunetide6andtideglusib7 trialswith
regard to clinical (age at symptomonset and recruitment), ge-
netic,and imagingprofilesandthedegreeofmotorand/or func-
tional impairment at study recruitment. In addition, our base-
linePSPRatingScaleandSEADLscores forpatientswithPSP-RS
were consistent with those seen in patients with PSP-RS re-
cruited to the 4RT neuroimaging initiative longitudinal
cohort.31
Use of the 2017MDS PSP criteria increased the number of
clinical PSP cases from 58 to 101, implying that non–
Richardson syndrome presentations (49 of 101 [48.5%]) are
common. The subcortical presentations of PSP, consisting of
PSP-parkinsonism and PSP-PGF phenotypes, have a long de-
lay to diagnosis that can at least in part be attributed to fre-
quent initial misdiagnoses as PD, because they share similar
clinical trajectories and initial clinical features. Although the
present study was not adequately powered to detect signifi-
cant differences between PSP and CBS subgroups and PD, we
were able todetect trendsof greater cognitive impairment and
higher levels of serumNF-L in thePSP-subcortical group com-
pared with PD.
The PSP-subcortical group had a more benign clinical
trajectory, less cognitive impairment, lower serum NF-L lev-
els, higher TRIM11 rs564309 minor allele frequency, and
more restricted midbrain and cortical atrophy than the
PSP-RS and PSP-cortical groups. However, we identified
midbrain atrophy to be a core neuroimaging feature of PSP
across the different subtypes, which may enable early sepa-
ration from Lewy body PD. The finding of higher serum NF-L
levels in the PSP-RS and PSP-cortical groups may indicate
higher disease intensity or be a consequence of greater corti-
cal atrophy seen in these phenotypes.
Pathologically proven CBS-AD and CBS-CBD may be dif-
ficult to distinguish in clinical practice.15,16 The advent of AD
biomarkers is likely to improve this differentiation.We found
that a biomarker-defined CBS-AD group had amilder clinical
trajectory, greaterventriculomegaly,higherAPOE-ε4allele fre-
quency, and greater cognitive impairment comparedwith the
CBS-4RT group. In particular, theACE-III revealed significant
differences in attention,memory, and language subscores be-
tween CBS-AD and CBS-4RT. Our data show that despite the
clinical overlap, CBS-AD can be distinguished from CBS-4RT
in life. This finding is further supported by the fact that both
of our CSF biomarker-defined CBS-4RT cases with postmor-
Table 2. Cognitive, Fluid Biomarker, and Imaging AUC Values FromROC Curve Analyses
Variablea
AUC by Group Comparison
Controls vs
PSP-All
Controls vs
CBS-All
PSP-All vs
CBS-All
PSP-RS vs
PSP-Cortical
PSP-RS vs
PSP-Subcortical
PSP-Cortical vs
PSP-Subcortical
CBS-AD vs
CBS-4RT
MoCA 0.84 0.79 0.66 0.75 0.83 0.80 0.87
ECAS 0.91 0.83 0.61 0.73 0.82 0.80 0.80
ACE-III 0.94 0.88 0.64 0.76 0.81 0.81 0.80
Serum NF-L 0.88 0.91 0.72 0.74 0.83 0.75 0.76
Pons-midbrain ratio 0.69 0.73 0.84 0.71 0.58 0.60 0.66
Imaging region
Pons 0.76 0.92 0.78 0.59 0.58 0.70 0.57
Midbrain 0.89 0.91 0.56 0.63 0.65 0.60 0.60
Medulla 0.78 0.82 0.51 0.54 0.59 0.52 0.69
Cerebellum 0.59 0.79 0.55 0.73 0.54 0.80 0.63
Frontal lobe 0.80 0.71 0.75 0.76 0.70 0.89 0.57
Parietal lobe 0.69 0.60 0.73 0.73 0.60 0.84 0.69
Temporal lobe 0.79 0.67 0.77 0.65 0.60 0.75 0.51
Occipital lobe 0.59 0.63 0.61 0.72 0.52 0.78 0.54
Central structures 0.88 0.81 0.74 0.62 0.50 0.64 0.57
Ventricles 0.71 0.51 0.81 0.60 0.68 0.79 0.66
Abbreviations: ACE-III, Addenbrooke’s Cognitive Examination 3; AD, Alzheimer
disease; AUC, area under the ROC curve; CBS, corticobasal syndrome;
ECAS, Edinburgh Cognitive and Behavioural ALS (Amytrophic Lateral Sclerosis)
Screen; 4RT, 4-repeat tau; MoCA, Montreal Cognitive Assessment;
NF-L, neurofilament light chain; PSP, progressive supranuclear palsy;
ROC, receiver operating characteristic; RS, Richardson syndrome.
a Cognitive scale and serumNF-L AUC values are based on logistic regression
analyses that used sex, age at symptom onset, and disease duration at testing
as covariates. Imaging group comparisons were adjusted for sex, age at scan,
and total intracranial volume. An AUC of 0.80 or greater indicated high
diagnostic accuracy.
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temevaluationhadCBDpathologic findings. Although all the
major syndromes studied herein are bilateral brain diseases,
CBS is typically asymmetrical, in contrast to PSP-RS andMSA.
Suchasymmetry canbequantifiedby a laterality indexofmo-
tor features, but less so in terms of cognitive asymmetry. We
thereforeopted forasimplegeneral linearmodel forMRIanaly-
sis without laterality. Further increases in the diagnostic ac-
curacy of MRImay be gained in future studies by incorporat-
ingphenotypic data, including laterality effects, in themodel.
To compare the discriminant usefulness of multimodal
biomarkers, accommodating widely different scales and
variances, we have also presented their performance as AUC
values for casesvscontrols andcomparisonsofdiseasegroups.
Using an AUC cutoff of at least 0.80 to represent high diag-
nostic accuracy, we confirmed the role of cognitive screening
scales in differentiatingCBS-AD fromCBS-4RTand the role of
cognitivescreeningscales, serumNF-L levels, andcorticalvolu-
metric MRI measures in differentiating PSP-subcortical from
PSP-RS and PSP-cortical. In addition, serumNF-L level (AUC,
0.80) was able to accurately distinguish PD from a combined
APS group consisting of all PSP and CBS cases. The compari-
son of Table 2 and eTables 3 and 5 in the Supplement high-
lights that the utility of a biomarker to discriminate patient
groups (such as the AUC) cannot simply be inferred from the
significance of an unpaired t test between groups, especially
where group sizes vary.
The2017MDSPSPdiagnostic criteriawerepublisheddur-
ing study recruitment, and so we are able to report the pro-
spectivecharacterizationofvariantPSPphenotypesusingclini-
cal, cognitive, fluidbiomarker, genetic, and imagingmeasures
with neuropathologic confirmation of diagnosis. In addition,
we present a biomarker-defined CBS-AD group that has dis-
tinct clinical, cognitive, andgenetic features that allow it to be
distinguished from CBS-4RT. We found that as many as 50%
of cases with PSP presented with nonclassic variant PSP phe-
notypes, and in retrospective case series, this frequency has
been shown to be as high as 76%.32 Until now, these PSP vari-
ants havebeenmissedby clinical, therapeutic, andepidemio-
logic studies that have largely focused on the classic PSP-RS
presentation.2-4,6,7 Similarly, asmanyas50%ofCBScaseswith
CSF analysis had a biomarker profile consistent with under-
lyingADpathologic features.Ofnote, our estimates arehigher
than thoseseen inasimilar-sized retrospectivecase serieswith
pathologic confirmation inwhich5of21CBScases (23.8%)had
primary pathologic AD findings at postmortem.15 Alongside
these phenotype-specificmarkers, our inclusion of data from
a large PD cohort allowed us to confirm that the use of serum
NF-L levels and cognitive screening scales may aid the early
differentiation of PD from APS.33,34
Limitations
We acknowledge limitations to the present study. First, most
ofour caseswerediagnosedusingclinical criteriawithoutneu-
ropathologic verification. Cases with CBS-4RT and CBS-AD
were defined using CSF biomarker criteria, and we acknowl-
edge that in late life, AD biomarker positivity may be coinci-
dental alongside CBD and does not prove that AD pathologic
features are the primary cause of the clinical symptoms. We
anticipate that follow-up of this natural history cohort, with
further cases undergoing postmortem assessment, will allow
us to validate the sensitivity and specificity of the clinical and
biomarker criteria used to stratify patients. Althoughnot cur-
rently available in our cohort, in-depth pathologic character-
ization of APS subtypes and associations with their antemor-
tembiomarkerprofiles are informative. Previously, pathologic
variants of PSP have been described.35 Of interest, that study
found a higher density of cortical tau pathology in variants of
PSP presenting with focal cortical syndromes comparedwith
PSP-parkinsonism and PSP-PGF, a finding that is in line
with differences in cortical atrophy seen in PSP-cortical vs
PSP-subcortical groups in our study. Our clinical disease tra-
jectory analyses were based on baseline clinical and func-
tional rating scale scores. We believe longitudinal data from
this cohortwill beessential to accurately characterize theclini-
cal progression of PSP andCBS and identifymarkers that pre-
dict and track progression. Although our AUC results are
promising, aswegathermore longitudinal data,weexpect the
diagnostic accuracy of PSP and CBS to further improvewith a
well-powered multivariate approach, including cross-
validated machine learning algorithms. Although a propor-
tion of our IDT cases will eventually have non-APS diagnoses
such as PD and vascular gait disorders, we expect that some
caseswill eventually fulfill diagnostic criteria for definedAPS,
representing cases that have been recruited at the very earli-
est disease stages.
Conclusions
ThePROSPECTstudy’smultimodal assessmentof clinical, cog-
nitive, fluid, genetic, and imaging data has identified mark-
ers that enable the differentiation of PD from PSP and CBS.
Inaddition,wepresentconfirmatorydataonthechangesacross
modalities in classical phenotypes of PSP and CBS and evalu-
ate biomarkers of variant PSP syndromes included in themost
recent diagnostic criteria and in a distinct biomarker-defined
CBS-AD syndrome. These findingsmay enhance the early di-
agnosis ofPSPandCBS for accurateprognosticationandstrati-
fication of patients for clinical trials.
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